Trelegy Ellipta vs Daliresp
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Trelegy Ellipta | US Daliresp | |
|---|---|---|
| Generic name | fluticasone/umeclidinium/vilanterol | roflumilast |
| Drug class | Inhaled Corticosteroid + LAMA + LABA | PDE4 Inhibitor (Oral) |
| Treats | COPD, asthma | Chronic obstructive pulmonary disease (COPD) |
| Category | Respiratory | Respiratory |
| Manufacturer | GSK | AstraZeneca |
| Year approved | 2017 | 2011 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $200M | — |
| Common side effects | Thrush, Respiratory infections, Headache, Cough | Diarrhea, Weight loss, Nausea, Headache |
Trelegy Ellipta
Frequently asked questions
Is Trelegy Ellipta or Daliresp better?
Neither is universally "better." Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) and Daliresp (roflumilast) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Trelegy Ellipta and Daliresp?
Trelegy Ellipta is a Inhaled Corticosteroid + LAMA + LABA made by GSK, while Daliresp is a PDE4 Inhibitor (Oral) made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Trelegy Ellipta has the larger estimated TV advertising budget of the two.